HealthResJ, health, medicine, nursing, research https://ejournals.epublishing.ekt.gr/index.php/HealthResJ/sitemap

Prevalence of familial hypercholesterolemia in Attica region, Greece


Published: Feb 11, 2021
Keywords:
Familial hypercholesterolemia prevalence risk cardiovascular disease
Niki Pavlatou
Nikoletta Rovina
Georgia Toylia
Olga Kadda
Christina Marvaki
Theodore Kapadochos
Genovefa Kolovou
Antonia Koutsoukou
Abstract

Background: Dyslipidemias are one of the major modifiable risk factors for cardiovascular disease. Familial hypercholesterolemia (FH) is the most common genetic metabolic disorder; it is estimated that around 14-34 million people worldwide have FH but only 25% of FH patients have been diagnosed. 

Aim: The aim of the present study was to explore the prevalence of FH in Attica region, Greece.

Methods: Attica region was divided into 8 regional units. A predesigned questionnaire was used to collect demographic and clinical data. Data analysis was performed by using the Statistical Package for the Social Sciences (SPSS), ver. 20.

Results: The studied sample consisted of 1578 Greek inhabitants of Attica region. The majority of the sample was women (59.9%). The mean age of the studied participants was 47.1 (±14.9) years. According to Simon Broome criteria, the probability of an FH diagnosis as unlikely is determined in 98.7% of the studied sample, probable in 0.8% of the participants or definite in 0.5% of the participants, based on this data, the prevalence of FH in Attica region, Greece is 1:200. Qualitative factors found to be associated with the onset of the disease were medication (p-value = 0.001) and hypolipidemic therapy (p-value = 0.001). The quantitative factors found to be associated with disease onset were body mass index (p-value = 0.044), and systolic (p-value = 0.001) and diastolic (p-value = 0.007) pressure.

Conclusions: Based on our data, the prevalence of FH in Attica region, Greece is 1:200. Early identification of contributing factors in FH development and proper treatment is vital and reduce the risk of premature and severe atherosclerotic disease.

Article Details
  • Section
  • Original Articles
Downloads
References
Heidenreich P, Trogdon, J.G., Khavjou, O.A., Butler, J., Dracup, K., Ezekowitz, M.D., et al. Forecasting the future of cardiovascular disease in the U.SA: A policy statement from American Heart Association. Circulation. 2011;123:933-9442.
Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117.
Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han X, Tang D, Chen R. Research Progress on the Relationship between Athero-sclerosis and Inflammation. Biomolecules. 2018;8:80.
Ndrepepa G. Atherosclerosis & ischaemic heart disease: Here to stay or gone tomorrow.Indian J Med Res. 2017;146:293-297.
On line: Statistics Explained. https://ec.europa.eu/eurostat/statisticsexplained/. Last ac-cessed: 28/11/2019.
Michas G, Karvelas G, Trikas A. Cardiovascular disease in Greece; the latest evidence on risk factors. Hellenic J Cardi-ol. 2019;60:271-275.
Vlachadis N, Iliodromiti Z, Vlachadi M, Xanthos T, Ktenas E, Vrachnis D, Kornarou E, Vrachnis N. Cardiovascular mortali-ty and the financial crisis in Greece: trends and outlook. Int J Cardiol. 2014;176:1367-8.
Pejic RN. Familial hypercholesterolemia.Ochsner J. 2014;14:669-72.
Ramasamy I.Update on the molecular biology of dyslipidemias.Clin Chim Acta. 2016;454:143-85.
Pitsavos C, Panagiotakos DB, Chrysohoou C, Stefanadis C. Epidemiology of cardiovascular risk factors in Greece: aims, design and baseline characteristics of the ATTICA study. BMC Public Health. 2003;3:32.
Kolovou G, Marvaki C, Makrygiannis S, Kadda O, Gianna-kopoulou V, Kalogeropoulos P, et al. Rationale and design of the Greek registry for familial hypercholesterolemia (GRegistry-FH) of the hellenic college of treatment of ath-erosclerosis (HCTA). Hellenic J Cardiol. 2019:S1109-9666(19)30281-7.
Rizos CV, Athyros V, Bilianou E, Chrousos G, Garoufi A, Ko-lovou G, et al. An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hy-percholesterolemia Registry (HELLAS-FH). Hormones (Ath-ens). 2017;16:306-312.
Al-Rasadi K, Al-Waili K, Al-Sabti HA, Al-Hinai A, Al-Hashmi K, Al-Zakwani I, et al.Criteria for Diagnosis of Familial Hy-percholesterolemia: A Comprehensive Analysis of the Dif-ferent Guidelines, Appraising their Suitability in the Omani Arab Population.Oman Med J. 2014;29:85-91.
Brunham LR, Ruel I, Khoury E, Hegele RA, Couture P, Ber-geron J, et al.Familial hypercholesterolemia in Canada: Ini-tial results from the FH Canada national regis-try.Atherosclerosis. 2018;277:419-424.
Béliard S, Boccara F, Cariou B, Carrié A, Collet X, Farnier M, et al; French FH Registry group.High burden of recurrent cardiovascular events in heterozygous familial hypercho-lesterolemia: The French Familial Hypercholesterolemia Registry.Atherosclerosis. 2018;277:334-340.
Kayikcioglu M, Tokgozoglu L, Dogan V, Ceyhan C, Tuncez A, Kutlu M, et al.What have we learned from Turkish famili-al hypercholesterolemia registries (A-HIT1 and A-HIT2)?Atherosclerosis. 2018;277:341-346.
Schmidt N, Dressel A, Grammer TB, Gouni-Berthold I, Julius U, Kassner U, et al.Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaRe-High Registry.Atherosclerosis. 2018;277:314-322.
Amor-Salamanca A, Castillo S, Gonzalez-Vioque E, Dominguez F, Quintana L, Lluís-Ganella C, et al. J Am Coll Cardiol. 2017; 70(14):1732-1740.
Pirazzi C, Håkansson L, Gustafsson C, Omerovic E, Wiklund O, Mancina RM.High prevalence of genetic determined familial hypercholesterolemia in premature coronary artery disease.Appl Clin Genet. 2019;12:71-78.
Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholes-terolemia: a HuGE prevalence review.Am J Epidemiol. 2004;160(5):407-20.
Wang Y, Li Y, Liu X, Tu R, Zhang H, Qian X, et al. The preva-lence and related factors of familial hypercholesterolemia in rural population of China using Chinese modified Dutch Lipid Clinic Network definition. BMC Public Health. 2019;19:837.
Thavendiranathan P, Jones E, Han RK, Cullen-Dean G, Hel-den E, Conner WT, et al. Association between physical ac-tivity, adiposity, and lipid abnormalities in children with familial hyperlipidemia. Eur J Cardiovasc Prev Rehabil. 2007;14:59-64.
Cui Y, Li S, Zhang F, Song J, Lee C, Wu M, Chen H. Preva-lence of familial hypercholesterolemia in patients with premature myocardial infarction. Clin Cardiol. 2019;42:385-390.
Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA. 2015;313(10):1029-1036.
Rizos CV, Elisaf MS, Skoumas I, Tziomalos K, Kotsis V, Rallidis L, et al. Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholester-olemia in Greece: Data from the Hellenic Familial Hyper-cholesterolemia Registry (HELLAS-FH).Atherosclerosis. 2018;277:308-313.
Dumitrescu A, Mosteoru S, Vinereanu D, Dan GA, Gaita L, Gaita D. Preliminary data of familial hypercholesterolemia (FH) patients in Romania. Atherosclerosis. 2018;277:304-307.
Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217.Eur Heart J. 2016;37:1384-94.
de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of Familial Hypercholes-terolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES).Circulation. 2016;133:1067-72.
Most read articles by the same author(s)